How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience

[1]  M. Çakan,et al.  Time to collaborate: Objectives, design, and methodology of PeRA-Research Group , 2021, Northern clinics of Istanbul.

[2]  F. Bagnasco,et al.  Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era , 2019, Arthritis Research & Therapy.

[3]  R. Schneider,et al.  2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis , 2019, Arthritis care & research.

[4]  N. Wulffraat,et al.  Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus , 2018, The Journal of Rheumatology.

[5]  T. Herlin,et al.  Clinical Outcome and Long-term Remission in JIA , 2017, Current Rheumatology Reports.

[6]  N. Menon,et al.  Clinical profile and juvenile arthritis damage index in children with juvenile idiopathic arthritis: A study from a tertiary care center in south India , 2016, International journal of rheumatic diseases.

[7]  E. Haddad,et al.  The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort , 2014, Annals of the rheumatic diseases.

[8]  R. Cron,et al.  Treatment of juvenile idiopathic arthritis in the biologic age. , 2013, Rheumatic diseases clinics of North America.

[9]  Bin Huang,et al.  Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. , 2012, Arthritis and rheumatism.

[10]  M. Beresford,et al.  Juvenile Idiopathic Arthritis , 2011, Paediatric drugs.

[11]  K. Aalto,et al.  Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE–JIA): a multicentre randomised open-label clinical trial , 2011, Annals of the rheumatic diseases.

[12]  Alberto Martini,et al.  2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features , 2011, Arthritis care & research.

[13]  A. Martini,et al.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.

[14]  J. Norris,et al.  Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis , 2007, Annals of the rheumatic diseases.

[15]  C. Wouters,et al.  A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[16]  R. Saurenmann,et al.  Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. , 2007, Arthritis and rheumatism.

[17]  Bin Huang,et al.  Patterns of clinical remission in select categories of juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[18]  A. Martini,et al.  Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[19]  A Ravelli,et al.  Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. , 2004, Clinical and experimental rheumatology.

[20]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[21]  B. Dijkmans,et al.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. , 2004, Arthritis and rheumatism.

[22]  M. Cheang,et al.  Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. , 2003, The Journal of rheumatology.

[23]  A. Zwinderman,et al.  Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. , 2003, The Journal of rheumatology.

[24]  Andre Peeters,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis , 2000 .

[25]  M. Okuni,et al.  Clinical analysis of 570 cases with juvenile rheumatoid arthritis: Results of a nationwide retrospective survey in Japan , 1997, Acta paediatrica Japonica : Overseas edition.

[26]  S. Bowyer,et al.  Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. , 1996, The Journal of rheumatology.

[27]  L. Tucker,et al.  Demography of a regional pediatric rheumatology patient population. Affiliated Children's Arthritis Centers of New England. , 1994, The Journal of rheumatology.

[28]  Atlanta,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. , 2008, Arthritis and rheumatism.